Making cures a reality: Clinical adoption of cell therapies
The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.
Breakthrough T1D and Partners Thank NIH Director For Commitment to Continuing Research in FY25
Breakthrough T1D and other research and patient advocacy organizations recently had the opportunity to meet with National Institute of Health…
Breakthrough T1D helps organize an event at the European Parliament about unmet needs for T1D and accelerating cures
This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D…
Son’s love inspires new name for Breakthrough T1D Center of Excellence in New England
The Center has been renamed The Breakthrough T1D Barbara Dewey Cammett Center of Excellence in New England.
Turning negatives into positives: Clearing up clinical trials misconceptions
This Clinical Trials Awareness Day, we’re exploring lessons from clinical trials and debunking clinical trials misconceptions.
Celiac disease and type 1 diabetes: What’s the connection?
What is the link between celiac disease and type 1 diabetes? Learn what celiac disease is, how it is treated,…
Medical Affairs team kicks off international islet cell therapy workshops at Breakthrough T1D HQ
Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.
New Breakthrough T1D publications highlight unmet needs and demographics of the T1D population
Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key…
Menstrual cycles, hormones, and T1D: What women need to know
Menstrual cycles and type 1 diabetes (T1D) have a lot in common: they can be unpredictable, inconsistent from person to…
Treating and preventing eye disease with type 1 diabetes
Diabetic eye disease is a troubling reality for many people living with type 1 diabetes, but research is helping reduce…
